The stage is set for a catalyst-packed 2016 for cancer diagnostics firm VolitionRx (NYSE:VNRX), reckons research house Edison.
It follows recently released data for its NuQ test in colorectal and lung cancer, which both exceeded results from previous trials, said analyst Maxim Jacobs.
The company is performing a screen of 4,700 patients for 27 types of cancer, with results expected in the second half of 2016, notes Edison.
Data from the first US trial of NuQ in prostate cancer at MD Anderson are expected in the first quarter of 2016 as well as three studies of CRC (colorectal cancer) and colon polyps due in the first half 2016 and the first prospective trial in endometriosis due in the second half.
Data from a 600-person, follow-up lung cancer trial are expected in the second half this year. Last month the group reported over 90% accuracy for its new cancer blood test in a study into colorectal cancer in Belgium.
The NuQ test identified 23 colorectal cancer sufferers out 121 patients tested, a 91% success rate.
Meanwhile, in November, the nucleosome-based tests accurately detected more than 90% of lung cancer cases in a study of 73 patients.
Edison has adjusted its valuation of the firm from US$10.48 per share to US$10.90 per share, mainly due to expectations of greater expense control.
VolitionRx had US$6.9mln in cash at the end of Q315 and is likely to raise capital in early 2016, it added.